BELLICUM PHARMACEUTICALS, INC Uncategorized Contracts & Agreements

Description of (Filed With SEC on March 31, 2023)

Cancer Research Grant Contract, dated July 27, 2011, by and between the Registrant and the Cancer Prevention and Research Institute of Texas (Filed With SEC on November 5, 2020)

Omnibus Amendment Agreement, dated October 3, 2014, by and between Registrant and ARIAD Pharmaceuticals, Inc (Filed With SEC on November 5, 2020)

Description of Securities (Filed With SEC on March 12, 2020)

Open Market Sale AgreementSM, dated October 5, 2018, by and between Bellicum Pharmaceuticals, Inc. and Jefferies LLC (Filed With SEC on October 5, 2018)

Cancer Research Grant Contract with the Cancer Prevention and Research Institute of Texas, dated August 9, 2017 (Filed With SEC on November 7, 2017)

Letter agreement by and between the registrant and Alan A. Musso, effective August 3, 2017 (Filed With SEC on November 7, 2017)

CO-DEVELOPMENT AND CO-COMMERCIALISATION AGREEMENT BETWEEN ADAPTIMMUNE LIMITED AND BELLICUM PHARMACEUTICALS, INC. (Filed With SEC on March 13, 2017)

BELLICUM PHARMACEUTICALS, INC. SPONSORED RESEARCH AGREEMENT NO. 2 (Filed With SEC on August 8, 2016)

Additional abbreviations may also be used though not in the above list. (Filed With SEC on December 9, 2014)

EXCLUSIVELICENSE AGREEMENT Re: BCM BLG # 13-040 Entitled Methods for Inducing Selective Apoptosis (Filed With SEC on November 18, 2014)

EXCLUSIVELICENSE AGREEMENT BAYLOR COLLEGE OF MEDICINE BELLICUM PHARMACEUTICALS, INC. (Filed With SEC on November 18, 2014)

OMNIBUSAMENDMENT AGREEMENT (Filed With SEC on November 18, 2014)

NOTICE OF EXPANSION OF LICENSED FIELD TO OBTAIN ADDITIONAL EXCLUSIVE RIGHTS (Filed With SEC on November 18, 2014)